NEW YORK – Lisen Imprinting Diagnostic (LisenID) on Tuesday said it has entered into an agreement with Mayo Clinic to research and develop diagnostic tests for early cancer detection.
The partnership combines LisenID's epigenetic imprinting technology, called QCIGISH (quantitative chromogenic imprinted gene in situ hybridization), with Mayo's clinical expertise, Wilmington, Delaware-based LisenID said.
QCIGISH is an RNA in situ hybridization method that can be used to quantify genomic imprinting alterations that are associated with various cancer types. The company claims on its website that its technology can detect at least 12 types of cancers at their earliest stages.
The initial focus of the Mayo collaboration is the research and development of a QCIGISH-based laboratory-developed test for early lung cancer detection using transbronchial needle aspiration samples, the company said. This test aims to provide a more accurate, objective, and clinically actionable tool for diagnosing malignancies in peripheral pulmonary lesions, which are challenging with current cytology-based methods, the company added.
Mayo Clinic has an undisclosed financial interest in the technology, LisenID said. Additional financial details were not disclosed.